Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F-18-fluorothymidine - National Cancer Institute

Drug Profile

F-18-fluorothymidine - National Cancer Institute

Alternative Names: 18-F-fluorothymidine; 18F-FLT - National Cancer Institute; 18F-fluorothymidine - National Cancer Institute; 3'-deoxy-3'-[18F] Fluorothymidine PET/CT scanning - National Cancer Institute; F-18-FLT; Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) - National Cancer Institute

Latest Information Update: 25 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer National Cancer Institute (USA); Radboud-University-Nijmegen-Medical-Centre; University of Washington
  • Class Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Glioma
  • No development reported Cancer metastases

Most Recent Events

  • 25 Aug 2015 Clinical development for Glioma (diagnosis) is ongoing in the USA
  • 25 Aug 2015 F-18-fluorothymidine is still in phase II trials for Breast cancer (Diagnosis) in the USA
  • 03 Feb 2014 Case Comprehensive Cancer Center and National Cancer Institute plan a clinical trial for Solid tumours (diagnosis) in USA (NCT02055586)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top